{
    "clinical_study": {
        "@rank": "68787", 
        "arm_group": {
            "arm_group_label": "Ozurdex Injection", 
            "arm_group_type": "Experimental", 
            "description": "Ozurdex Intravitreal Injection (0.7 mg)"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether an intravitreal dexamethasone implant\n      (Ozurdex, Allergan) is effective to manage macular edema secondary to non-infectious\n      uveitis."
        }, 
        "brief_title": "TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Macular Edema", 
            "Uveitis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Edema", 
                "Macular Edema", 
                "Uveitis", 
                "Chorioretinitis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Uveitis accounts for more than 10% of all cases of severe vision loss in developed\n      countries, which makes it possibly the fourth leading cause of blindness in the United\n      States. Cystoid macular edema (CME) is the most structural complication of uveitis,\n      resulting in visual impairment and blindness. If left untreated or undertreated over a\n      period of years, CME may result in permanent photoreceptor damage of the macula and loss of\n      central vision. Further, CME may persist despite adequate control of the uveitis, and\n      therefore, adjuvant therapy to specifically treat the CME may be required.\n\n      We propose to study whether a sustained steroid delivery system (Ozurdex, Allergan) can\n      treat uveitic macular edema.  Ozurdex has been proven to be effective for non-infectious\n      posterior uveitis; and FDA approved for posterior uveitis.  The sustained delivery of the\n      steroid and local delivery modality makes it an ideal candidate to manage macular edema in\n      uveitis."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Uveitis CME with central subfoveal thickness > 350 microns\n\n          -  non-infectious uveitis\n\n          -  Visual Acuity > 20/32\n\n        Exclusion Criteria:\n\n          -  Visual Acuity worse than 20/200\n\n          -  Moderate or severe glaucoma (as defined as >2 topical ocular medications)\n\n          -  Infectious uveitis\n\n          -  Patients with active or suspected ocular or periocular infections including most\n             viral diseases of the cornea and conjunctiva, including active epithelial herpes\n             simplex keratitis, vaccinia, varicella, mycobacterial infections, and fungal\n             diseases.\n\n          -  Aphakic eyes with rupture of the posterior lens capsule\n\n          -  Anterior Chamber intraocular Lens and rupture of the posterior lens capsule\n\n          -  Hypersensitivity to any components of the Ozurdex"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01870440", 
            "org_study_id": "NCRVA-2013-Ozurdex-16.2"
        }, 
        "intervention": {
            "arm_group_label": "Ozurdex Injection", 
            "description": "Intravitreal Injection", 
            "intervention_name": "Ozurdex Intravitreal Injection (0.7 mg)", 
            "intervention_type": "Drug", 
            "other_name": "Ozurdex (0.7 mg)"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Uveitis", 
            "Macular Edema"
        ], 
        "lastchanged_date": "June 15, 2013", 
        "location": {
            "contact": {
                "email": "laguda@ncrva.com", 
                "last_name": "Lisa Aguda, LVN", 
                "phone": "650-988-7467"
            }, 
            "contact_backup": {
                "email": "sdepaz@ncrva.com", 
                "last_name": "Sharon Depaz", 
                "phone": "650-988-7467"
            }, 
            "facility": {
                "address": {
                    "city": "Mountain View", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94040"
                }, 
                "name": "Northern California Retina Vitreous Associates"
            }, 
            "investigator": {
                "last_name": "Rahul N Khurana, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "TAHOE: Sustained InTravitreal DexAmetHasone Implant (Ozurdex) for Uveitic Macular Edema", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Best Corrected Visual Acuity (using Early Treatment Diabetic Retinopathy Study Protocal)", 
            "safety_issue": "No", 
            "time_frame": "Day 90"
        }, 
        "reference": {
            "PMID": "21220619", 
            "citation": "Lowder C, Belfort R Jr, Lightman S, Foster CS, Robinson MR, Schiffman RM, Li XY, Cui H, Whitcup SM; Ozurdex HURON Study Group. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011 May;129(5):545-53. doi: 10.1001/archophthalmol.2010.339. Epub 2011 Jan 10."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01870440"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Northern California Retina Vitreous Associates", 
            "investigator_full_name": "Rahul Khurana, M.D.", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Central Subfoveal Retinal Thickness", 
                "safety_issue": "No", 
                "time_frame": "Day 90"
            }, 
            {
                "measure": "Central Subfoveal Retinal Thickness", 
                "safety_issue": "No", 
                "time_frame": "Day 180"
            }, 
            {
                "measure": "Best Corrected Visual Acuity", 
                "safety_issue": "No", 
                "time_frame": "Day 180"
            }
        ], 
        "source": "Northern California Retina Vitreous Associates", 
        "sponsors": {
            "collaborator": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Northern California Retina Vitreous Associates", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}